Tenax Therapeutics, Inc. (TENX) Stock Price & Analysis

Tenax Therapeutics, Inc. (TENX) closed at USD 1.72 on Friday, October 23, 2026, down 2.27% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 1.76; the Oct 23, 2026 session ranged USD 1.69–1.76 on volume of 852,031 shares. Market capitalization is $64.37M, with a 52-week range of USD 1.31–19.4 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:39 UTC.

Also available as compact Markdown for AI agents: nexqual.com/TENX.md

Key facts (TENX)

• Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$64.9M (SEC filings).
• Insider open-market purchases, last ~7 months: 7 Form 4 filings, $6.4M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.30 on a 1–5 scale) (10 analysts), mean target USD 9.63 (range 4–35).
• Total return with dividends: 1Y -76.7% vs S&P 500 +13.4%; 5Y -99.9% vs S&P 500 +76.9%.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TENX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (TENX)

P/B 0.6x · Earnings yield -100.77%

Insider purchases (SEC Form 4, open-market, last ~7 months) (TENX)

7 purchases, $6.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (TENX)

Consensus Buy (mean 2.30 on a 1–5 scale), 10 analysts; mean target USD 9.63 (low 4, high 35).

Rating changes, last 120 days:

Total return (dividends reinvested) (TENX)

TENX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 10, 2026.

TENX company outlook (results filed Jul 31, 2026)

• “EX-99.1 2 d90330dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc.”
• “As we announced at the start of July, we expect to have topline data from the LEVEL clinical trial in August," said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "In parallel, our team continues to activate sites and advance enrollment in LEVEL-2, our second global pivotal trial.”
• “We expect to complete LEVEL-2 enrollment by the end of 2027.”
• “Proceeds of $13.4 million during the second quarter from exercises of previously issued warrants has enabled Tenax to extend its cash runway, and the Company now expects to fund its operations through the second quarter of 2028.”

Quoted word-for-word from the SEC 8-K results press release.

TENX analyst estimates and revisions

Key Statistics (as of October 24, 2026 at 12:39 UTC)

Technical Analysis (TENX)

Nexqual's technical model rates TENX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:39 UTC.

Analyst Ratings (TENX)

Wall Street analysts rate TENX "Buy" based on 10 analysts, with a mean price target of USD 9.63 (range USD 4–35), per Nexqual as of October 24, 2026 at 12:39 UTC.

Earnings (TENX)

Recent Earnings History

Source: Nexqual, October 24, 2026 at 12:39 UTC.

Financials & Fundamentals (TENX)

Source: Nexqual, October 24, 2026 at 12:39 UTC.

Financial Health Score (TENX)

Nexqual rates Tenax Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 12:39 UTC.

Ownership (TENX)

Source: Nexqual, October 24, 2026 at 12:39 UTC.

Leadership (TENX)

Tenax Therapeutics, Inc. is led by Christopher T. Giordano, CEO, President & Director, per Nexqual as of October 24, 2026 at 12:39 UTC.

Major Backers & Investors (TENX)

Notable institutional backers of Tenax Therapeutics, Inc. include FMR, LLC, Vivo Capital, LLC, Perceptive Advisors Llc, according to Nexqual as of October 24, 2026 at 12:39 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 24, 2026 at 12:39 UTC.

From Tenax Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)

Key Strengths & Strategy (as disclosed to the SEC)

• In February 2022, the FDA provided a written response advising that the safety database required for filing a New Drug Application ("NDA") only needs to meet two of the three minimum International Clinical Harmonization ("ICH") standards for a chronic medication in treating a non-life-threatening condition: 300 patients treated for 6 months, and 100 patients treated for 12 months.
• We believe this strategy will help us develop a portfolio of high-quality product development opportunities, enhance our clinical development and commercialization capabilities, and increase our ability to generate value from our proprietary technologies.
• We rely on a combination of patent applications, patents, trade secrets, proprietary know-how, trademarks, and contractual provisions to protect our proprietary rights.
• As of the date of this filing, we have been granted four U.S. patents, and have been notified of the impending granting of a Canadian, a European, and a fifth U.S. patent, all related to product candidates and proprietary process, method and technology.

Partnerships

• Through our agreement with our licensor, Orion Corporation, we have access to a library of ongoing and completed trials and research projects, including certain documentation, which we believe, in combination with positive Phase 3 data we hope to generate in at least one indication, will support FDA approval of levosimendan.
• On January 4, 2022, we received a patent from the United States Patent and Trademark Office ("USPTO") for the subcutaneous administration of levosimendan (TNX-102), whether through the prototype formulation we have developed in collaboration with a formulation development partner, or other subcutaneous formulations meeting certain broad characteristics defined in the patent.

Legal & Regulatory Risks (Item 1A, quoted)

• Additional laws and regulations may also be enacted that could prevent or delay regulatory approval of our products, including laws or regulations relating to the price or cost-effectiveness of medical products. Any delay or failure to achieve regulatory approval of commercial sales of our products is likely to have a material adverse effect on our financial condition, results of operations and cash flows.
• Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing products and limit commercialization of any products that we may develop.
• We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our technology.
• Our share price has been volatile, and may continue to be volatile, which may subject us to securities class action litigation in the future.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:39 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt